Riskpilot← Back to searchSign inGet full accessNovozymes Biopharma DK A/S
A/SActiveCVR 29603537Krogshøjvej 36Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20062 employees
Revenue 2024
DKK 12,8M
+1301% vs 2023
EBITDA margin
100.0%
+1301% vs 2023
Equity ratio
78.1%
Financial strength
Net profit 2024
DKK 11,5M
-23% vs 2023
| Revenue | DKK 12,8M | +1301% |
| EBITDA | DKK 12,8M | +1301% |
| Net profit | DKK 11,5M | -23% |
| Total assets | DKK 29,4M | -61% |
| Equity | DKK 23M | -68% |
| Employees | 2 | — |
Legal name
Novozymes Biopharma DK A/S
CVR number
29603537
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
29. maj 2006
Share capital
DKK 612.000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af et bestyrelsesmedlem eller af en direktør
Company purpose
Selskabets formål er drift af og investering i forskning, udvikling, produktion og handel med biologiske løsninger, herunder lægemidler, bioteknologiske produkter og processer samt at drive virksomhed, der efter bestyrelsens nærmere bestemmelse står i forbindelse hermed. Selskabet tilstræber at drive sin virksomhed på bæredygtig og ansvarlig vis, herunder i økonomisk, miljømæssig og social henseende
Address
Krogshøjvej 36
Phone
+4544460000
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 47.194 | 58.720 | -399 | 912 | 12.771 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 47.194 | 58.720 | -399 | 912 | 12.771 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | 47.194 | 58.720 | -399 | 912 | 12.771 |
| Net financials | 5.428 | 6.291 | 266.127 | 18.201 | 2.028 |
| Profit before tax | 52.622 | 65.012 | 265.728 | 19.112 | 14.799 |
| Tax | 11.460 | 13.893 | -338 | 4.205 | 3.256 |
| Net profit | 41.162 | 51.119 | 266.066 | 14.908 | 11.543 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 167.512 | 123.196 | 322.996 | 75.920 | 29.430 |
| Equity | 97.354 | 108.473 | 321.539 | 71.447 | 22.990 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 13.459 | 14.723 | 1.457 | 4.473 | 6.439 |
| Total debt | 13.459 | 14.723 | 1.457 | 4.473 | 6.439 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20202024
Equity ratio
78.1%
This company
38.2%
Market median
+104% vs market
20202024
Return on equity
50.2%
This company
18.4%
Market median
+173% vs market
20202024
Net profit margin
90.4%
This company
8.1%
Market median
+1016% vs market
20202024
Asset turnover
0.43×
This company
1.12×
Market median
-62% vs market
20202024
Debt / equity
0.28×
This company
0.62×
Market median
+55% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MV Management | Management | 2018 |
| Former (2) | ||
PA Chief Executive Officer | Chief Executive Officer | 2006 – 2006 |
PR Chief Executive Officer | Chief Executive Officer | 2016 – 2018 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2023 | |
| Chairman | 2024 | |
| Former (11) | ||
| Board of Directors | 2016 – 2018 | |
| Deputy Chairman | 2015 – 2016 | |
| Chairman | 2007 – 2010 | |
| Board of Directors | 2016 – 2018 | |
| Board of Directors | 2006 – 2006 | |
| Deputy Chairman | 2016 – 2021 | |
| Board of Directors | 2021 – 2023 | |
| Chairman | 2016 – 2018 | |
| Chairman | 2018 – 2024 | |
| Deputy Chairman | 2018 – 2021 | |
| Chairman | 2006 – 2007 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2006 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
Novozymes Biopharma DK A/S Board members of Novozymes Biopharma DK A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Artur Fredrik Månsson | Chief Executive Officer | 0 companies |
| Mikkel Viltoft | Management | 0 companies |
| Peter Rosholm | Chief Executive Officer | 0 companies |
| Søren Knud Carlsen | Board of Directors | 0 companies |
| Rainer Chapour Lehmann | Board of Directors | 0 companies |
| Benny Dalgaard Loft | Deputy Chairman | 0 companies |
| Kristian Merser | Chairman | 0 companies |
| Gunnar Magnus Severus Modée Persson | Board of Directors | 0 companies |
| Niels Herman Münter | Board of Directors | 0 companies |
| Thomas Videbæk | Deputy Chairman | 0 companies |
| Lisbet Kragelund | Chairman | 0 companies |
| Lars Green | Board of Directors | 0 companies |
| Joseph Donald deBethizy | Chairman | 0 companies |
| Randi Camilla Kinch Jensen | Chairman | 0 companies |
| Tina Sejersgård Fanø | Deputy Chairman | 0 companies |
| Steen Riisgaard | Chairman | 0 companies |